VolitionRX (NYSEAMERICAN:VNRX) Stock Passes Below 50-Day Moving Average – Here’s What Happened

Shares of VolitionRX Limited (NYSEAMERICAN:VNRX) crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $2.76 and traded as low as $1.32. VolitionRX shares last traded at $1.39, with a volume of 228,591 shares traded.

Analysts Set New Price Targets

Several research analysts have weighed in on VNRX shares. D. Boral Capital reaffirmed a “hold” rating on shares of VolitionRX in a research note on Monday, April 20th. Benchmark reaffirmed a “hold” rating on shares of VolitionRX in a research note on Tuesday, June 2nd. HC Wainwright lowered their price objective on shares of VolitionRX from $30.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. Finally, Citigroup lowered shares of VolitionRX to a “hold” rating in a research note on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $40.00.

VolitionRX Price Performance

The company’s 50 day moving average price is $2.65 and its 200 day moving average price is $4.19. The firm has a market cap of $11.91 million, a PE ratio of -0.33 and a beta of 1.04.

VolitionRX (NYSEAMERICAN:VNRX) last posted its quarterly earnings data on Thursday, May 14th. The medical research company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.27). The firm had revenue of $0.99 million for the quarter, compared to analyst estimates of $1.52 million. Sell-side analysts expect that VolitionRX Limited will post -2.4 earnings per share for the current fiscal year.

Institutional Trading of VolitionRX

Several hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in VolitionRX in the third quarter valued at approximately $28,000. Northwestern Mutual Wealth Management Co. acquired a new stake in VolitionRX in the second quarter valued at approximately $52,000. Geode Capital Management LLC raised its holdings in VolitionRX by 9.8% in the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock valued at $246,000 after acquiring an additional 85,816 shares in the last quarter. Jane Street Group LLC acquired a new stake in VolitionRX in the fourth quarter valued at approximately $28,000. Finally, Squarepoint Ops LLC acquired a new stake in VolitionRX in the fourth quarter valued at approximately $34,000. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.